Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

MiRacle Consortium Receives a € 1.2 Million FP7 Grant from the European Union

Published: Monday, November 04, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer – acronym: MiRacle.

InteRNA Technologies B.V. and VU University Medical Center (VUmc) announce today they have been granted funding from the European Union’s FP7program “Research for the benefit of SMEs”. InteRNA and VUmc, who are leading this consortium, together with Quiet Therapeutics Ltd (Israel), a biopharma SME engaged in the development of a new class of highly selective targeted therapeutics for oncology and inflammation, have been granted around € 1.2 million, to develop the targeted delivery of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer. The consortium further includes BioSpring (Germany), OctoPlus (the Netherlands) and the Laboratory of Pharmacology and Toxicology LPT (Germany).

MiRacle focuses on the development of a targeted therapeutic formulation for the treatment of head and neck cancer. Head and neck (H&N) cancer is the sixth most common cancer worldwide and the incidence increases. Unfortunately the majority of H&N cancer patients present with advanced stages of disease. These patients frequently develop locoregional recurrences, distant metastasis and/or second primary tumors resulting in 5-years survival rates of less than 60% The development of novel anti-cancer agents to improve outcome is therefore urgently awaited.

The goal of MiRacle is the advancement of the safe, targeted delivery of therapeutic tumor-selective lethal miRNA formulation towards the clinic by combining two innovative technologies, i.e. application of therapeutic miRNAs using cancer cell-specific targeted drug delivery.

Besides the expertise on the therapeutic application of miRNA and the in depth knowledge of the therapeutic indication, e.g. H&N cancer, the MiRacle consortium brings together the knowledge on the synthesis of biochemical active miRNAs, the expertise in drug formulation to specifically deliver therapeutic miRNA into humans, the understanding for synthesis of complex drug formulations, the preclinical testing, and the skillfulness in toxicity tests that are required for RNA based drug registration.

 “The unique tumor-selective lethal miRNAs identified display a very interesting biology and potential therapeutic effect that warrants further development towards the clinic. This FP7 grant exemplifies that with this consortium we have all the expertise in place to bring a tumor killing miRNA in a targeted and safe manner towards registration for first in human testing”, said Roel Schaapveld, Chief Executive Officer of InteRNA Technologies.

“This FP7 grant enables the next step in the translation of the tumor-selective lethal microRNAs that we discovered” said Ruud Brakenhof, Professor of Cancer Genetics, Tumor Biology Section at the Department of Otolaryngology/Head-Neck Surgery of VUmc.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InteRNA Technologies, UCB and University of Bonn to Collaborate
Agreement on the role of microRNAs in neurodegenerative disease.
Friday, January 10, 2014
InteRNA Technologies Announces Closing of Equity Financing Round
Company secures additional equity financing to progress lead program for melanoma treatment.
Friday, September 06, 2013
InteRNA Technologies Receives Notice of Allowance from USPTO
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.
Tuesday, October 16, 2012
InteRNA Technologies Receives Notice of Allowance for miRNA Sequences of its Lead Pre-Clinical Product
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.
Monday, October 15, 2012
Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos